Fresenius Medical Care, the world’s largest provider of dialysis products and services, is expanding its peritoneal dialysis (PD) product range with the introduction of two new dialysis fluids. Both products contain pure bicarbonate buffers and have considerably reduced amounts of glucose degradation products (UltraLow GDP). The new fluids – bicaVera® low calcium and bicaNova® – will allow therapy to be adjusted more precisely to the individual patient’s needs in terms of calcium or buffer concentration.

bicaVera® and bicaNova® regulate the acid-base balance through a pure bicarbonate buffer, while the low calcium concentrations in these PD dialysis fluids follow the recent International Society of Peritoneal Dialysis (ISPD) guidelines.

The two new PD fluids were presented this month at the 2017 European Dialysis and Transplantation Association/European Renal Association (ERA-EDTA) congress in Madrid. They will be introduced in steps in several European markets.

In peritoneal dialysis, the lining of a patient’s abdominal cavity – the peritoneum – acts as the filter for cleaning the blood. Of the approximately 3 million dialysis patients around the world, about 350,000 choose peritoneal dialysis treatment.

Fresenius Medical Care offers a wide range of products for Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD). These include various dialysis fluids, bag systems, cyclers for APD, and the related bag and tube systems.

For medical professionals, more information about the peritoneal dialysis products of Fresenius Medical Care is available at